Paper No. ____

Filed: July 11, 2014

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

BIODELIVERY SCIENCES INTERNATIONAL, INC. Petitioner

v.

RB PHARMACEUTICALS LIMITED Patent Owner.

Case IPR2014-00998 Patent 8,475,832

PATENT OWNER MANDATORY NOTICE INFORMATION UNDER 37 C.F.R. § 42.8(a)(2)



I. REAL PARTY-IN-INTEREST

The real parties-in-interest are RB Pharmaceuticals Limited (Patent Owner), the sole owner of U.S. Patent No. 8,475,832 ('832 patent), and Reckitt Benckiser Pharmaceuticals, Inc. (RBP), the exclusive licensee of the '832 patent in the U.S. Both companies are subsidiaries of the same parent company, Reckitt Benckiser Group plc. Patent Owner's address is 103-105 Bath Road, Slough, UK. RBP's address is 10710 Midlothian Turnpike, Suite 430, Richmond, Virginia.

Pursuant to a written agreement with RBP, MonoSol Rx, LLC (MonoSol) has exclusive manufacturing rights under the '832 patent and therefore is an implied, exclusive licensee thereunder. MonoSol is also the original assignee of the patent, and the named inventors were, and in some cases remain, MonoSol employees. To the extent these facts are sufficient to render MonoSol a real party-in-interest, Patent Owner also identifies MonoSol under 37 CFR § 42.8(b)(1). MonoSol's address is 30 Technology Drive, Warren, New Jersey.

II. RELATED MATTERS

The Petition is substantially redundant of the petition filed by the same petitioner in IPR2014-00325, which was filed almost six months ago. The present Petition is directed to the same claims of the same patent as the earlier petition, involves the same parties, asserts the same or substantially the same contentions,



and is based on a subset of the references cited in the earlier petition. *See* Petition at 2-3.

The '832 patent was previously asserted against Petitioner in *Reckitt* Benckiser Pharmaceuticals, Inc., RB Pharmaceuticals Limited, and MonoSol Rx, LLC. v. BioDelivery Sciences International, Inc., E.D.N.C. Civil Action No. 5:13cv-760-BO. That action was subsequently dismissed without prejudice as premature on procedural grounds. The '832 patent has also been asserted in Reckitt Benckiser Pharmaceuticals, Inc., RB Pharmaceuticals Limited, and MonoSol Rx, LLC. v. Par Pharmaceutical, Inc., and IntelGenx Technologies, Corp., D. Del. Civil Action No. 13-1461-RGA; Reckitt Benckiser Pharmaceuticals, Inc., RB Pharmaceuticals Limited, and MonoSol Rx, LLC. v. Watson Laboratories, Inc., D. Del. Civil Action No. 13-1674-RGA; Reckitt Benckiser Pharmaceuticals, Inc., RB Pharmaceuticals Limited, and MonoSol Rx, LLC. v. Alvogen Pine Brook, Inc., D. Del. Civil Action No. 13-2003-RGA; and Reckitt Benckiser Pharmaceuticals, Inc., RB Pharmaceuticals Limited, and MonoSol Rx, LLC. v. Par Pharmaceutical, Inc., and IntelGenx Technologies, *Corp.*, D. Del. Civil Action No. 14-422-RGA. The 13-1674 (Watson) and 14-422 (Par) Actions remain pending. (The 13-1461 (Par) and 13-2003 (Alvogen) Actions were dismissed without prejudice in light of Par and Alvogen having prematurely



triggered the Hatch-Waxman ANDA litigation process in regard to those Actions.)

U.S. Application No. 13/964,975, which is a continuation of U.S.

Application No. 13/923,749 (now abandoned), which was a continuation of U.S.

Application No. 12/537,571 ('571 application, now the '832 patent), is pending.

U.S. Application No. 12/537,580, which was filed at the same time as, and shares a portion of the specification of, the '571 application is pending and may also potentially be affected by a decision in the proceeding herein.

III. LEAD AND BACKUP COUNSEL AND SERVICE INFORMATION

Lead Counsel:

James M. Bollinger, Esq. Troutman Sanders LLP The Chrysler Building 405 Lexington Avenue New York, NY 10174

Tel: (212) 704-6113 Fax: (212) 704-5954

Email: james.bollinger@troutmansanders.com

Registration No. 32,555

Backup Counsel:

Daniel A. Ladow, Esq. Troutman Sanders LLP The Chrysler Building 405 Lexington Avenue New York, NY 10174

Tel: (212) 704-6218 Fax: (212) 704-5929

Email: daniel.ladow@troutmansanders.com

Pro hac vice admission to be sought



Counsel consent to electronic service at their email addresses.

IV. PATENT OWNER PRELIMINARY RESPONSE

Patent Owner reserves the right to file a preliminary response at a later date.

Dated: July 11, 2014	/James M. Bollinger/
	James M. Bollinger
	Reg. No. 32,555



DOCKET

Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

